Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Disease marker combination enhances patient characterization in the Finnish sarcoidosis patients.

Lahtela E, Wolin A, Pietinalho A, Lokki ML, Selroos O.

Respir Med. 2017 Nov;132:92-94. doi: 10.1016/j.rmed.2017.09.014. Epub 2017 Oct 3.

PMID:
29229112
2.

SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility-A Joint Analysis in Four European Populations.

Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CHM, Eklund A, Grutters JC, Kolek V, Mrazek F, Kishore A, Padyukov L, Pietinalho A, Ronninger M, Seppänen M, Selroos O, Lokki ML.

Front Immunol. 2017 Apr 19;8:422. doi: 10.3389/fimmu.2017.00422. eCollection 2017.

3.

Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma.

Asher I, Haahtela T, Selroos O, Ellwood P, Ellwood E; Global Asthma Network Study Group.

Allergol Immunopathol (Madr). 2017 Mar - Apr;45(2):105-114. doi: 10.1016/j.aller.2016.10.013. Epub 2017 Feb 1.

PMID:
28161283
4.

The Finnish experience to save asthma costs by improving care in 1987-2013.

Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä RL, Selroos O, Reissell E.

J Allergy Clin Immunol. 2017 Feb;139(2):408-414.e2. doi: 10.1016/j.jaci.2016.12.001. Epub 2016 Dec 12.

PMID:
27979429
5.

Revisiting early intervention in adult asthma.

Haahtela T, Selroos O, O'Byrne PM.

ERJ Open Res. 2015 Sep 14;1(1). pii: 00022-2015. eCollection 2015 May. Review.

6.

Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.

Müller V, Gálffy G, Orosz M, Kováts Z, Odler B, Selroos O, Tamási L.

Int J Chron Obstruct Pulmon Dis. 2016 Jan 12;11:93-101. doi: 10.2147/COPD.S92331. eCollection 2016.

7.

National and regional asthma programmes in Europe.

Selroos O, Kupczyk M, Kuna P, Łacwik P, Bousquet J, Brennan D, Palkonen S, Contreras J, FitzGerald M, Hedlin G, Johnston SL, Louis R, Metcalf L, Walker S, Moreno-Galdó A, Papadopoulos NG, Rosado-Pinto J, Powell P, Haahtela T.

Eur Respir Rev. 2015 Sep;24(137):474-83. doi: 10.1183/16000617.00008114. Review.

8.

Dry-powder inhalers in acute asthma.

Selroos O.

Ther Deliv. 2014 Jan;5(1):69-81. doi: 10.4155/tde.13.132. Review.

PMID:
24341818
9.

Clinical relevance is associated with allergen-specific wheal size in skin prick testing.

Haahtela T, Burbach GJ, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet J, Bousquet-Rouanet L, Bousquet PJ, Bresciani M, Bruno A, Canonica GW, Darsow U, Demoly P, Durham SR, Fokkens WJ, Giavi S, Gjomarkaj M, Gramiccioni C, Kowalski ML, Losonczy G, Orosz M, Papadopoulos NG, Stingl G, Todo-Bom A, von Mutius E, Köhli A, Wöhrl S, Järvenpää S, Kautiainen H, Petman L, Selroos O, Zuberbier T, Heinzerling LM.

Clin Exp Allergy. 2014 Mar;44(3):407-16. doi: 10.1111/cea.12240.

10.

Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.

Gálffy G, Mezei G, Németh G, Tamási L, Müller V, Selroos O, Orosz M.

Drugs R D. 2013 Sep;13(3):215-22. doi: 10.1007/s40268-013-0027-3.

11.

Major histocompatibility complex class II and BTNL2 associations in sarcoidosis.

Wennerström A, Pietinalho A, Lasota J, Salli K, Surakka I, Seppänen M, Selroos O, Lokki ML.

Eur Respir J. 2013 Aug;42(2):550-3. doi: 10.1183/09031936.00035213. No abstract available.

12.

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study.

van Schayck OC, Haughney J, Aubier M, Selroos O, Ekström T, Ostinelli J, Buhl R.

Respir Med. 2012 Feb;106(2):189-96. doi: 10.1016/j.rmed.2011.10.017. Epub 2011 Nov 26.

13.

HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis.

Wennerström A, Pietinalho A, Vauhkonen H, Lahtela L, Palikhe A, Hedman J, Purokivi M, Varkki E, Seppänen M, Lokki ML, Selroos O; Finnish Sarcoidosis Study Group.

Hum Immunol. 2012 Jan;73(1):93-100. doi: 10.1016/j.humimm.2011.10.016. Epub 2011 Oct 23.

PMID:
22074998
14.

Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children--not too much, not too little.

Turpeinen M, Pelkonen AS, Selroos O, Nikander K, Haahtela T.

Thorax. 2012 Feb;67(2):100-2. doi: 10.1136/thoraxjnl-2011-200246. Epub 2011 Oct 28. No abstract available.

PMID:
22038795
15.

Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

Aubier M, Haughney J, Selroos O, van Schayck OC, Ekström T, Ostinelli J, Buhl R.

Ther Adv Respir Dis. 2011 Oct;5(5):289-98. doi: 10.1177/1753465811407236. Epub 2011 May 17. Erratum in: Ther Adv Respir Dis. 2012 Aug;6(4):247.

PMID:
21586508
16.

Comparing asthma treatment in elderly versus younger patients.

Haughney J, Aubier M, Jørgensen L, Ostinelli J, Selroos O, van Schayck CP, Buhl R.

Respir Med. 2011 Jun;105(6):838-45. doi: 10.1016/j.rmed.2011.02.011. Epub 2011 Mar 23.

17.

True adherence with the Turbuhaler in young children with asthma.

Nikander K, Turpeinen M, Pelkonen AS, Bengtsson T, Selroos O, Haahtela T.

Arch Dis Child. 2011 Feb;96(2):168-73. doi: 10.1136/adc.2010.187724. Epub 2010 Nov 19.

PMID:
21097795
18.

Unaffected peak inspiratory flow through Turbuhaler during histamine inhalation challenge.

Nikander K, Turpeinen M, Pelkonen AS, Selroos O, Haahtela T.

Allergy. 2011 Feb;66(2):302-3. doi: 10.1111/j.1398-9995.2010.02471.x. Epub 2010 Aug 30. No abstract available.

PMID:
20804463
19.

Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy.

Aubier M, Buhl R, Ekström T, Ostinelli J, van Schayck CP, Selroos O, Haughney J.

Eur Respir J. 2010 Sep;36(3):524-30. doi: 10.1183/09031936.00022010. Epub 2010 Jul 1.

20.

Bone mineral density in children treated with daily or periodical inhaled budesonide: the Helsinki Early Intervention Childhood Asthma study.

Turpeinen M, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen-Backman K, Haahtela T.

Pediatr Res. 2010 Aug;68(2):169-73. doi: 10.1203/00006450-201011001-00329.

PMID:
20485203
21.

Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma.

Haahtela T, Tamminen K, Kava T, Malmberg LP, Rytilä P, Nikander K, Persson T, Selroos O.

J Allergy Clin Immunol. 2009 Dec;124(6):1180-5. doi: 10.1016/j.jaci.2009.09.036.

PMID:
20004779
22.

Skin thickness in children treated with daily or periodical inhaled budesonide for mild persistent asthma. The Helsinki early intervention childhood asthma study.

Turpeinen M, Raitio H, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen-Backman K, Haahtela T.

Pediatr Res. 2010 Feb;67(2):221-5. doi: 10.1203/PDR.0b013e3181c6e574.

PMID:
19858777
23.

Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children.

Obase Y, Rytilä P, Metso T, Pelkonen AS, Tervahartiala T, Turpeinen M, Mäkelä M, Saarialho-Kere U, Selroos O, Sorsa T, Haahtela T.

Int Arch Allergy Immunol. 2010;151(3):247-54. doi: 10.1159/000242362. Epub 2009 Sep 29.

PMID:
19786805
24.

Use of dry powder inhalers in acute exacerbations of asthma and COPD.

Selroos O, Borgström L, Ingelf J.

Ther Adv Respir Dis. 2009 Apr;3(2):81-91. doi: 10.1177/1753465809103737. Epub 2009 May 14. Review.

PMID:
19443520
25.

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.

Ställberg B, Selroos O, Vogelmeier C, Andersson E, Ekström T, Larsson K.

Respir Res. 2009 Feb 19;10:11. doi: 10.1186/1465-9921-10-11.

26.

Ophthalmologic findings in children with asthma receiving inhaled budesonide.

Pelkonen A, Kari O, Selroos O, Nikander K, Haahtela T, Turpeinen M.

J Allergy Clin Immunol. 2008 Oct;122(4):832-834. doi: 10.1016/j.jaci.2008.07.013. Epub 2008 Aug 28. No abstract available.

PMID:
18760462
27.

Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function.

Rytilä P, Ghaly L, Varghese S, Chung W, Selroos O, Haahtela T; Airway Inflammation Study Group.

Eur Respir J. 2008 Oct;32(4):989-96. doi: 10.1183/09031936.00062307. Epub 2008 May 28.

28.

Effect of disease duration on dose-response of inhaled budesonide in asthma.

Selroos O.

Respir Med. 2008 Jul;102(7):1065-72. doi: 10.1016/j.rmed.2007.12.029. Epub 2008 Apr 2. Erratum in: Respir Med. 2008 Dec;102(12):1845.

30.

Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?

Edsbäcker S, Wollmer P, Selroos O, Borgström L, Olsson B, Ingelf J.

Pulm Pharmacol Ther. 2008;21(2):247-58. Epub 2007 Sep 6. Review.

PMID:
17950641
31.
32.

Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study.

Haahtela T, Tamminen K, Malmberg LP, Zetterström O, Karjalainen J, Ylä-Outinen H, Svahn T, Ekström T, Selroos O.

Eur Respir J. 2006 Oct;28(4):748-55.

34.

Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study.

Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, Ekström T, Selroos O.

Curr Med Res Opin. 2006 May;22(5):809-21.

PMID:
16709303
35.

Formoterol Turbuhaler as reliever medication in patients with acute asthma.

Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Selroos O.

Eur Respir J. 2006 Apr;27(4):735-41. Epub 2006 Feb 2.

37.

Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation.

Selroos O, Edsbäcker S, Hultquist C.

J Asthma. 2004;41(8):771-90. Review.

PMID:
15641626
38.

The place of inhaled corticosteroids in chronic obstructive pulmonary disease.

Selroos O.

Curr Med Res Opin. 2004 Oct;20(10):1579-93. Review.

PMID:
15462691
39.
40.

Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.

Boonsawat W, Charoenratanakul S, Pothirat C, Sawanyawisuth K, Seearamroongruang T, Bengtsson T, Brander R, Selroos O.

Respir Med. 2003 Sep;97(9):1067-74.

41.

The EDICT study.

Selroos O, Ekström T, Hultquist C.

Respir Med. 2003 Apr;97(4):446; author reply 447-8. No abstract available.

42.

Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma.

Ind PW, Villasante C, Shiner RJ, Pietinalho A, Böszörményi NG, Soliman S, Selroos O.

Eur Respir J. 2002 Oct;20(4):859-66.

43.

Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation.

Selroos O, Ekström T.

Pulm Pharmacol Ther. 2002;15(2):175-83. Review.

PMID:
12090792
44.

No evidence of glucocorticosteroid-induced apoptosis of airway epithelial cells In vivo.

Miller-Larsson A, Selroos O.

Am J Respir Crit Care Med. 2002 Jun 1;165(11):1567; author reply 1567-8. No abstract available.

PMID:
12045136
45.

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction.

Malolepszy J, Böszörményi Nagy G, Selroos O, Larsso P, Brander R.

Eur Respir J. 2001 Dec;18(6):928-34. Erratum in: Eur Respir J 2002 Feb;19(2):384. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

46.

Early treatment of stage II sarcoidosis improves 5-year pulmonary function.

Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group.

Chest. 2002 Jan;121(1):24-31.

PMID:
11796428
47.

Formoterol used as needed--clinical effectiveness.

Selroos O.

Respir Med. 2001 Aug;95 Suppl B:S17-20.

48.

Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma.

Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O; Japanese Pulmicort Turbuhaler Study Group.

Respirology. 2001 Mar;6(1):27-35.

PMID:
11264760
49.

A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler study group.

Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O.

Respirology. 2000 Sep;5(3):247-56.

PMID:
11022987
50.

A double-blind, placebo-controlled steroid-sparing study with budesonide Turbuhaler in Japanese oral steroid-dependent asthma patients. Japanese Pulmicort Turbuhaler study group.

Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O.

Respirology. 2000 Sep;5(3):231-40.

PMID:
11022985

Supplemental Content

Loading ...
Support Center